Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old

NCT00590837 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT00590837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00590837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2008
Completion date
December 31, 2013
Enrollment
459 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia